CXL with epithelial disruption safely and effectively treats ectasia

Article

Corneal collagen crosslinking (CXL) with epithelial disruption appears to safely and effectively treat keratoconus or iatrogenic corneal ectasia, according to a study recently published in Eye. In fact, patients may tolerate the approach better than they tolerate the technique involving complete removal of the epithelium, say the authors, from the Corneoplastic Unit and Eye Bank of Queen Victoria Hospital in East Grinstead, UK.

Corneal collagen crosslinking (CXL) with epithelial disruption appears to safely and effectively treat keratoconus or iatrogenic corneal ectasia, according to a study recently published in Eye. In fact, patients may tolerate the approach better than they tolerate the technique involving complete removal of the epithelium, say the authors, from the Corneoplastic Unit and Eye Bank of Queen Victoria Hospital in East Grinstead, UK.

The researchers retrospectively reviewed case notes of 128 eyes with progressive keratoconus or iatrogenic corneal ectasia; all had undergone CXL using the technique involving the mechanical disruption of the epithelium. Thin corneas had been treated with hypotonic riboflavin; all others were treated with isotonic riboflavin.

At the 12-month point, 41.8% of patients in whom isotonic riboflavin had been used saw improved uncorrected visual acuity (UCVA), and 29.7% experienced improved best spectacle-corrected visual acuity (BSCVA). Only 13.4% lost UCVA lines, and 14.9% lost BSCVA.

At that same time point, 75% of patients treated with hypotonic riboflavin had BSCVA stability, and 25% had stable Kmax. Also, 25% of them had improved VA, and 58.3% experienced Kmax regression.

 

The short-term complication rate was similar to that of studies using the epithelium-off technique.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.